Severe drug-induced skin reactions: Clinical features, diagnosis, etiology, and therapy;Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diagnostik, Ätiologie und Therapie

JDDG - Journal of the German Society of Dermatology

Volumn 13, Issue 7, 2015, Pages

  Paulmann, Maren ^a   Mockenhaupt, Maja ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DILTIAZEM; DIPYRONE; HERBACEOUS AGENT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LAMOTRIGINE; MACROLIDE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; QUINOLONE DERIVATIVE; SALAZOSULFAPYRIDINE; SULFONAMIDE; TERBINAFINE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN; TOPICAL ANTIINFECTIVE AGENT;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AGE; ALLERGY TEST; ARTICLE; BULLOUS SKIN DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRESS SYNDROME; EUROSCAR SCORE; GENERALIZED BULLOUS FIXED DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; INCIDENCE; LABORATORY TEST; PATHOGENESIS; PROGNOSIS; RECURRENT DISEASE; SKIN BIOPSY; SKIN DISEASE ASSESSMENT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADRENAL CORTEX HORMONES; ALLOPURINOL; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTICONVULSANTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; TREATMENT OUTCOME;

EID: 84933502970     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12747     Document Type: Article

References (27)

1. Mockenhaupt M. Schwere arzneimittelinduzierte Hautreaktionen. Hautarzt 2014; 65: 415-23.
2. Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist Br J Dermatol 2007; 156(3): 609-11.
3. Liss Y, Mockenhaupt M. AGEP und DRESS erfordern rasche Intervention. Der Deutsche Dermatologe 2013; 2: 102-9.
4. Sidoroff A, Halevy S, Bouwes Bavinck JN et al. Acute generalized exanthematous pustulosis (AGEP)-A clinical reaction pattern. J Cutan Pathol 2001; 28: 113-9.
5. Hotz C, Valeyrie-Allanore L, Haddad C et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study of 58 patients. Br J Dermatol 2013; 169: 1223-32.
6. Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009; 9: 322-8.
7. Sidoroff A, Dunant A, Viboud C et al. Risk factors for acute generalized exanthematous pustulosis (AGEP) results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157: 989-96.
8. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250-7.
9. Kardaun SH, Sekula P, Valeyrie-Allanore L et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 1071-80.
10. Mockenhaupt M. Severe cutaneous adverse drug reactions. In: Burgdorf WHC, Plewig G, Wolff HH, Landthaler M. Braun-Falco's Dermatology, Heidelberg: Springer 2009; 473-84.
11. Gishlain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8: 5.
12. Funck-Brentano E, Duong TA, Bouvresse S et al. Therapeutic management of DRESS: A retrospective study of 38 cases. J Am Acad Dermatol 2015; 72: 246-52.
13. Lipowicz S, Sekula P, Ingen-Housz-Oro S et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2013; 168: 726-32.
14. Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 2002; 138: 1019-24.
15. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
16. Rzany B, Hering O, Mockenhaupt M et al. Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Br J Dermatol 1996; 135: 6-11.
17. Rzany B, Mockenhaupt M, Baur S et al. Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992). Structure and results of a population-based registry. J Clin Epidemiol 1996; 49: 769-73.
18. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol 2008; 128: 35-44.
19. Chronopoulos A, Pleyer U, Mockenhaupt M. Okuläre Beteiligung bei Stevens-Johnson-Syndrom und Toxisch epidermaler Nekrolyse. Klein Monatsbl Augenheilkd 2012; 229: 534-9.
20. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6.
21. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
22. Schneck J, Fagot JP, Sekula P et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
23. Valeyrie-Allanore L, Wolkenstein P, Brochard L et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010; 163: 847-53.
24. Barbaud A. Skin Testing and Patch Testing in Non-IgE-Mediated Drug Allergy. Curr Allergy Astham Rep 2014; 14: 442.
25. Kano Y, Hirahara K, Mitsuyama Y et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the time of drug eruption. Allergy 2007; 62: 1439-44.
26. Su SC, Chung WH. Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Sinica 2013; 31: 175-80.
27. Pichler WJ, Wendland T, Hausmann O et al. DRESS (Drug rash with eosinophilia and systemic symptoms). Eine schwere, oft verkannte Medikamentenallergie 2011; 11: 879-84.